TAKE Solutions Limited (TAKE.NS)
INR 8.0
(-0.37%)
INR 8.0
(-0.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 370.85 Million INR | -20.02% |
| 2022 | 463.69 Million INR | -40.54% |
| 2021 | 779.9 Million INR | -85.81% |
| 2020 | 5.49 Billion INR | -8.84% |
| 2019 | 6.02 Billion INR | 27.21% |
| 2018 | 4.73 Billion INR | 46.91% |
| 2017 | 3.22 Billion INR | 35.93% |
| 2016 | 2.37 Billion INR | -25.31% |
| 2015 | 3.17 Billion INR | 99.67% |
| 2014 | 1.59 Billion INR | -22.93% |
| 2013 | 2.06 Billion INR | 21.84% |
| 2012 | 1.69 Billion INR | 4.2% |
| 2011 | 1.62 Billion INR | -11.77% |
| 2010 | 1.84 Billion INR | 436.67% |
| 2009 | 343.52 Million INR | 44.18% |
| 2008 | 238.26 Million INR | -20.5% |
| 2007 | 299.71 Million INR | -78.36% |
| 2006 | 1.38 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 427.98 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 370.85 Million INR | -20.02% |
| 2023 Q4 | 370.85 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 521.55 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 463.69 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 463.69 Million INR | -40.54% |
| 2021 Q2 | 4.79 Billion INR | 0.0% |
| 2021 Q4 | 779.9 Million INR | 0.0% |
| 2021 FY | 779.9 Million INR | -85.81% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 5.49 Billion INR | 0.0% |
| 2020 Q2 | 5.37 Billion INR | 0.0% |
| 2020 FY | 5.49 Billion INR | -8.84% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 5.57 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 6.02 Billion INR | 0.0% |
| 2019 FY | 6.02 Billion INR | 27.21% |
| 2018 Q2 | 3.21 Billion INR | 0.0% |
| 2018 FY | 4.73 Billion INR | 46.91% |
| 2018 Q4 | 4.73 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.99 Billion INR | 0.0% |
| 2017 FY | 3.22 Billion INR | 35.93% |
| 2017 Q4 | 3.22 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 2.37 Billion INR | 0.0% |
| 2016 Q2 | 2.27 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 2.37 Billion INR | -25.31% |
| 2015 FY | 3.17 Billion INR | 99.67% |
| 2015 Q4 | 3.17 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 2.1 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.54 Billion INR | 0.0% |
| 2014 FY | 1.59 Billion INR | -22.93% |
| 2014 Q4 | 1.59 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 2.06 Billion INR | 21.84% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.73 Billion INR | 0.0% |
| 2013 Q4 | 2.06 Billion INR | 0.0% |
| 2012 FY | 1.69 Billion INR | 4.2% |
| 2012 Q4 | 1.69 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.9 Billion INR | 0.0% |
| 2011 FY | 1.62 Billion INR | -11.77% |
| 2011 Q4 | 1.62 Billion INR | 0.0% |
| 2010 FY | 1.84 Billion INR | 436.67% |
| 2009 FY | 343.52 Million INR | 44.18% |
| 2008 FY | 238.26 Million INR | -20.5% |
| 2007 FY | 299.71 Million INR | -78.36% |
| 2006 FY | 1.38 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biocon Limited | 162.76 Billion INR | 99.772% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -2199.132% |
| Concord Biotech Limited | 97.37 Million INR | -280.843% |
| Dishman Carbogen Amcis Limited | 23.12 Billion INR | 98.396% |
| Jubilant Ingrevia Limited | 7.4 Billion INR | 94.99% |
| Lyka Labs Limited | 586.5 Million INR | 36.769% |
| Panacea Biotec Limited | 209.9 Million INR | -76.679% |
| Piramal Pharma Limited | 47.1 Billion INR | 99.213% |
| SMS Lifesciences India Limited | 1 Billion INR | 63.181% |
| Supriya Lifescience Limited | 54.88 Million INR | -575.747% |
| Syngene International Limited | 5.55 Billion INR | 93.32% |
| Zota Health Care Limited | 952.84 Million INR | 61.08% |